Nyxoah (NASDAQ:NYXH) Price Target Lowered to $10.00 at Stifel Nicolaus

Nyxoah (NASDAQ:NYXH) had its price target cut by investment analysts at Stifel Nicolaus from $11.00 to $10.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 214.47% from the company’s previous close.

Several other equities analysts also recently weighed in on NYXH. Cantor Fitzgerald upgraded Nyxoah to a “strong-buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nyxoah has an average rating of “Moderate Buy” and a consensus target price of $11.33.

Nyxoah Trading Up 2.9%

Shares of NASDAQ:NYXH traded up $0.09 during trading on Friday, reaching $3.18. The stock had a trading volume of 61,860 shares, compared to its average volume of 50,782. The business has a fifty day moving average price of $4.37 and a 200-day moving average price of $4.86. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.40. The stock has a market cap of $108.31 million, a P/E ratio of -1.28 and a beta of 1.56. Nyxoah has a fifty-two week low of $3.04 and a fifty-two week high of $11.87.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Thursday, March 19th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). The firm had revenue of $6.62 million for the quarter, compared to analyst estimates of $5.70 million. Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%. As a group, analysts anticipate that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. raised its holdings in shares of Nyxoah by 35.6% in the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares during the period. Bank of America Corp DE increased its position in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares in the last quarter. Citadel Advisors LLC purchased a new position in Nyxoah in the third quarter valued at approximately $98,000. Deutsche Bank AG lifted its position in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after buying an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC purchased a new stake in Nyxoah during the second quarter worth approximately $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.